RNL BIO CO LTD

RNL BIO sumitted IND for pase II and III clinical trial to Korea FDA to treat cerebral palsy using autologous fat derived stem cells.

Two autologous stem cell therapy sessions prevented patient from foot amputation

-Electromyogram (EMG) findings show improvement in conduction speed and latency -RNL Bio’s stem cell therapy demonstrates effective outcomes

Patient’s own fat-derived stem cell cured severe atopic syndrome

Korean-FDA approved RNL’s Astrostem based on patient’s own fat derived stem cells to treat spinal cord injury. Phase I human trial will be done by intravenous infusion of stem cells at Sam Hospital in Anyang, South Korea

RNL Bio successfully cloned a small breed Pekingese commercially for the first time in the world.

As a promotion from RNL Bio, pet owners who register RNL's stem cell bank for animals will have unique opportunity for free stem cell therapy for their pets.

RNL Bio successfully treated a horse with syndesmitis and it will return to race track soon.

RNL Bio made another breakthrough in dog cloning history. Two clones were born from a Beagle donor's stem cells instead of skin cells.

Intravenous delivery of adipose derived stem cells showed effects on liver function restoration